Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes

American Journal of Physiology - Endocrinology and Metabolism

Volumn 297, Issue 5, 2009, Pages

  Saberi, Maziyar ^a   Bjelica, David ^a   Schenk, Simon ^a   Imamura, Takeshi ^a   Bandyopadhyay, Gautam ^a   Li, Pingping ^a   Jadhar, Vasant ^b   Vargeese, Chandra ^b   Wang, Weimin ^b   Bowman, Keith ^b   Zhang, Ye ^b   Polisky, Barry ^b   Olefsky, Jerrold M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sirna Therapeutics Inc   (United States)

Author keywords

Diabetes; Small interfering RNA; Transducer of regulated cAMP responsive element binding protein activity 2

Indexed keywords

GLUCOSE 6 PHOSPHATASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSDUCER OF REGULATED CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN ACTIVITY 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; INSULIN SENSITIVITY; LIVER CELL; LIVER TOXICITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; HEPATOCYTES; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; PYRUVIC ACID; RATS; RATS, ZUCKER; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 70350447639     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00158.2009     Document Type: Article

References (34)

1. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117: 3623-3632, 2007. (Pubitemid 350224068)
2. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 55: 2277-2285, 2006. (Pubitemid 44743625)
3. Canettieri G, Koo SH, Berdeaux R, Heredia J, Hedrick S, Zhang X, Montminy M. Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab 2: 331-338, 2005.
4. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exper Biol Med/Soc Exper Biol Med 173: 68-75, 1983.
5. Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38: 550-557, 1989. (Pubitemid 19125601)
6. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 24: 644-649, 2004. (Pubitemid 38451598)
7. Dentin R, Hedrick S, Xie J, Yates J, 3rd, Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science 319: 1402-1405, 2008. (Pubitemid 351354877)
8. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, Yates J, 3rd, Montminy M. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449: 366-369, 2007. (Pubitemid 47443476)
9. Ferrannini E, Groop LC. Hepatic glucose production in insulin-resistant states. Diabetes Metab Rev 5: 711-726, 1989. (Pubitemid 20097248)
10. Firth R, Bell P, Rizza R. Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity. Metab Clin Exper 36: 1091-1095, 1987. (Pubitemid 18025037)
11. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, Spiegelman B, Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413: 179-183, 2001. (Pubitemid 32867880)
12. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9: 1491-1497, 2003. (Pubitemid 38004776)
13. Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, Chiu CC, Chuang WL, Tsai TR, Yu ML. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 22: 2118-2123, 2007. (Pubitemid 350145601)
14. Imamura T, Huang J, Usui I, Satoh H, Bever J, Olefsky JM. Insulin-induced GLUT4 translocation involves protein kinase C-lambda-mediated functional coupling between Rab4 and the motor protein kinesin. Mol Cell Biol 23: 4892-4900, 2003. (Pubitemid 36793335)
15. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, Olefsky JM. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Invest 68: 957-969, 1981. (Pubitemid 11023523)
16. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, Hedrick S, Xu W, Boussouar F, Brindle P, Takemori H, Montminy M. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437: 1109-1111, 2005. (Pubitemid 41509342)
17. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 10: 530-534, 2004. (Pubitemid 38667913)
18. Krebs M, Roden M. Nutrient-induced insulin resistance in human skeletal muscle. Curr Med Chem 11: 901-908, 2004. (Pubitemid 38425922)
19. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42: 113-116, 1999. (Pubitemid 29039748)
20. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 90: 1323-1327, 1992.
21. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716, 2007. (Pubitemid 350207685)
22. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39: 1381-1390, 1990. (Pubitemid 20372227)
23. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007, 2005. (Pubitemid 41114035)
24. Nagle CA, An J, Shiota M, Torres TP, Cline GW, Liu ZX, Wang S, Catlin RL, Shulman GI, Newgard CB, Coleman RA. Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance. J Biol Chem 282: 14807-14815, 2007.
25. Neschen S, Morino K, Hammond LE, Zhang D, Liu ZX, Romanelli AJ, Cline GW, Pongratz RL, Zhang XM, Choi CS, Coleman RA, Shulman GI. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn- 3-phosphate acyltransferase 1 knockout mice. Cell Metab 2: 55-65, 2005. (Pubitemid 43239825)
26. Olefsky JM, Courtney CH. Type 2 diabetes mellitus: etiology, pathogenesis, and natural history. In: Endocrinology, edited by DeGroot LJ, Jameson JL, deKrestser D, Grossman AB, Marshall JC, Melmed S, Potts JT, and Weir GC. Philadelphia, PA: W. B. Saunders, 2005, p. 1093-1117.
27. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29: 351-366, 2008. (Pubitemid 351679704)
28. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 29: 81-90, 2006.
29. Rondinone CM. Therapeutic potential of RNAi in metabolic diseases. BioTechniques Suppl: 31-36, 2006.
30. Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 254: 573-576, 1991. (Pubitemid 21917377)
31. Seifter S, Dayton S, et al. The estimation of glycogen with the anthrone reagent. Arch Biochem 25: 191-200, 1950.
32. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82: 420-430, 1959.
33. Tayek JA, Katz J. Glucose production, recycling, and gluconeogenesis in normals and diabetics: a mass isotopomer [U-13C]glucose study. Am J Physiol Endocrinol Metab 270: E709-E717, 1996. (Pubitemid 126756544)
34. Wincott F, DiRenzo A, Shaffer C, Grimm S, Tracz D, Workman C, Sweedler D, Gonzalez C, Scaringe S, Usman N. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res 23: 2677-2684, 1995.